Indegene Ltd

About Indegene Ltd

Indegene Ltd is a digital-first commercialization company empowering the global life sciences industry. It provides technology-led solutions across drug development, clinical trials, and commercialization, helping biopharmaceutical, emerging biotech, and medical device companies enhance sales, improve market access, and optimize customer engagement through data-driven strategies and omnichannel approaches.

Key Financial Ratios of Indegene Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Indegene Ltd's P/E ratio (TTM) is 68.80, compared to the industry median of 32.53 and large cap median of 32.53.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Indegene Ltd's P/B ratio is 4.66, compared to the industry median of 3.84 and large cap median of 3.84.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Indegene Ltd's P/S ratio is 4.21, compared to the industry median of 3.46 and large cap median of 3.46.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Indegene Ltd's PEG ratio is 1.66.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Indegene Ltd's EV/EBITDA ratio is 21.70.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Indegene Ltd's ROE is 12.77%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Indegene Ltd's ROA is 13.40%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Indegene Ltd's ROCE is 19%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Indegene Ltd's operating margin is 17.64%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Indegene Ltd's net margin is 11.42%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Indegene Ltd's current ratio is 1.27.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Indegene Ltd's debt-to-equity ratio is 0.04.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Indegene Ltd's interest coverage ratio is 28.63.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Indegene Ltd's DPS is ₹2.16.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Indegene Ltd's EPS is -1.77.

(Source line: "Ratios as of 05 Nov 2026, based on last traded price of ₹605.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1998

• Headquarters: Bengaluru, Karnataka

• Core Offerings: Enterprise Commercial Solutions, Omnichannel Activation, Medical & Regulatory, R&D and Clinical Solutions

• Stock Listing: NSE (INDGN), BSE (544172)

• Promoter: Manish Gupta, Rajesh Nair, Dr. Sanjay Parikh, Gaurav Kapoor, Vivek Gupta

History of Indegene Ltd

Indegene was founded in 1998 by a team of entrepreneurs. Initially focused on providing integrated scientific and marketing solutions to pharmaceutical companies, it evolved into a digital-first commercialization company. Over two decades, it expanded its service offerings and global presence, leveraging technology and analytics to serve biopharmaceutical, emerging biotech, and medical device companies. The company successfully completed its Initial Public Offering (IPO) in May 2024, listing on NSE and BSE.

Business Segments and Revenue Mix

• Enterprise Commercial Solutions: Provides commercial strategy, sales enablement, and launch support, helping clients accelerate product adoption and revenue generation.

• Omnichannel Activation: Delivers personalized and integrated customer experiences across multiple digital and traditional channels, optimizing engagement with healthcare professionals.

• Medical & Regulatory: Offers solutions for medical affairs, pharmacovigilance, and regulatory compliance, ensuring scientific accuracy and adherence to industry standards.

• R&D and Clinical Solutions: Supports early-stage drug development, clinical trial operations, and data management, leveraging technology to enhance efficiency and insights.

Key Personnel

Manish Gupta, Co-founder, Chairman & CEO. He is a serial entrepreneur with over 25 years of experience in the life sciences and healthcare industry, driving Indegene's strategic vision and global expansion.

Subsidiaries and Associate Companies

['Indegene, Inc. (USA)', 'Indegene Pte Ltd (Singapore)', 'Indegene UK Limited (UK)', 'Indegene China Co., Ltd (China)', 'Crescendo World, Inc. (USA)', 'DMD Marketing Corp (USA)']

Corporate Actions

Initial Public Offering (IPO) in May 2024. No other major recent corporate actions on record.

References

1. Indegene Ltd IPO Red Herring Prospectus (RHP) 2. Exchange Filings (NSE/BSE) 3. Financial Results Announcement